Discontinued Operations - Summary of discontinued operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Schedule of Equity Method Investments [Line Items]
Provision for income tax expense
Net income from discontinued operations		$ 14,602		$ 28,915
9.5% Non-Recourse 2035 Notes
Schedule of Equity Method Investments [Line Items]
Interest rate (as a percent)	9.50%	9.50%	9.50%	9.50%
Disposed of by Sale | TRC | Royalty Pharma
Schedule of Equity Method Investments [Line Items]
Income from investments in TRC, LLC		$ 28,127		$ 53,237
Transaction-related legal expenses (prior to July 20, 2022)		(3,778)		(5,057)
Net income from discontinued operations		14,602		28,915
Disposed of by Sale | TRC | Royalty Pharma | 9.5% Non-Recourse 2035 Notes
Schedule of Equity Method Investments [Line Items]
Interest expense on 9.5% Non-recourse notes due 2035		$ (9,747)		$ (19,265)